MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

DexCom Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

67.28 -1.39

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

66.29

Max

68.17

Pagrindiniai rodikliai

By Trading Economics

Pajamos

17M

152M

Pardavimai

119M

1.1B

P/E

Sektoriaus vid.

47.409

63.778

Pelnas, tenkantis vienai akcijai

0.45

Pelno marža

13.624

Darbuotojai

10,200

EBITDA

5M

242M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+51.41% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-04-24

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-7.9B

26B

Ankstesnė atidarymo kaina

68.67

Ankstesnė uždarymo kaina

67.28

Naujienos nuotaikos

By Acuity

15%

85%

27 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

DexCom Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-10-25 09:10; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

2024-07-26 20:16; UTC

Uždarbis

These Stocks Moved the Most Today: DexCom, 3M, Nvidia, Bristol Myers, Coursera, Biogen, Charter, Deckers, and More -- Barrons.com

2024-07-26 09:13; UTC

Svarbiausios naujienos
Karštos akcijos

Stocks to Watch: DexCom, Coinbase, 3M, Hermès -- WSJ

2024-07-26 08:56; UTC

Svarbiausios naujienos

These Stocks Are Moving the Most Today: DexCom, Deckers, Coursera, Ford, Alphabet, Bristol Myers, 3M, and More -- Barrons.com

2024-06-27 16:01; UTC

Uždarbis

ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

DexCom Inc Prognozė

Kainos tikslas

By TipRanks

51.41% į viršų

12 mėnesių prognozė

Vidutinis 103.4 USD  51.41%

Aukščiausias 120 USD

Žemiausias 82 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines DexCom Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

16

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

66.25 / 72.47Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

27 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.